HedgeChatter

  • Home /
  • Tag Archives

GILD

1:37 am Gilead Sciences announces Phase 2 results for two investigational all-oral sofosbuvir-based regimens for the treatment of Chronic Hepatitis C

moreView todays social media effects on GILDView the latest stocks trending across Twitter. Click to view dashboardSee who Gilead is hiring next, click here to view […]

April 11, 2014 Bystocknews , Comments Off on 1:37 am Gilead Sciences announces Phase 2 results for two investigational all-oral sofosbuvir-based regimens for the treatment of Chronic Hepatitis C read more

Gilead Announces Results from Study of Sovaldi® for Retreatment of Chronic Hepatitis C in Patients Not Cured with Prior Antiviral Therapy

moreView todays social media effects on GILDView the latest stocks trending across Twitter. Click to view dashboardSee who Gilead is hiring next, click here to view […]

April 10, 2014 Bystocknews , Comments Off on Gilead Announces Results from Study of Sovaldi® for Retreatment of Chronic Hepatitis C in Patients Not Cured with Prior Antiviral Therapy read more

Gilead Announces Phase 2 Results for Two Investigational All-Oral Sofosbuvir-Based Regimens for the Treatment of Chronic Hepatitis C

moreView todays social media effects on GILDView the latest stocks trending across Twitter. Click to view dashboardSee who Gilead is hiring next, click here to view […]

April 10, 2014 Bystocknews , Comments Off on Gilead Announces Phase 2 Results for Two Investigational All-Oral Sofosbuvir-Based Regimens for the Treatment of Chronic Hepatitis C read more

8:31 am Gilead Sciences announces the FDA has granted priority review to the co’s NDA for a once-daily fixed-dose combination of the NS5A inhibitor ledipasvir 90 mg and the nucleotide analog polymerase inhibitor sofosbuvir 400 mg

moreView todays social media effects on GILDView the latest stocks trending across Twitter. Click to view dashboardSee who Gilead is hiring next, click here to view […]

April 8, 2014 Bystocknews , Comments Off on 8:31 am Gilead Sciences announces the FDA has granted priority review to the co’s NDA for a once-daily fixed-dose combination of the NS5A inhibitor ledipasvir 90 mg and the nucleotide analog polymerase inhibitor sofosbuvir 400 mg read more

MannKind vs. Idenix: Better Biotech Buy

moreView todays social media effects on GILDView the latest stocks trending across Twitter. Click to view dashboardSee who Gilead is hiring next, click here to view […]

April 7, 2014 Bystocknews , Comments Off on MannKind vs. Idenix: Better Biotech Buy read more

There’s still value in biotech stocks: Citi pro

moreView todays social media effects on GILDView the latest stocks trending across Twitter. Click to view dashboardSee who Gilead is hiring next, click here to view […]

April 7, 2014 Bystocknews , Comments Off on There’s still value in biotech stocks: Citi pro read more

Stress Free Portfolio: Q1 2014 Results

moreView todays social media effects on GILDView the latest stocks trending across Twitter. Click to view dashboardSee who Gilead is hiring next, click here to view […]

April 4, 2014 Bystocknews , Comments Off on Stress Free Portfolio: Q1 2014 Results read more

4:30 pm Gilead Announces Results From Phase 3 Study of Sofosbuvir Among Hepatitis C Patients in Japan; The study met its primary efficacy endpoint

moreView todays social media effects on GILDView the latest stocks trending across Twitter. Click to view dashboardSee who Gilead is hiring next, click here to view […]

April 3, 2014 Bystocknews , Comments Off on 4:30 pm Gilead Announces Results From Phase 3 Study of Sofosbuvir Among Hepatitis C Patients in Japan; The study met its primary efficacy endpoint read more